title: Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.
abstract: Metastatic renal cell cancer is one of the immuno-sensitive tumors. Apart from the immuno-modulating agents IFNalpha and IL-2, thalidomide has been reported to be effective in this type of cancer. However, bone metastases and bulky metastases, show limited response to immunotherapy, are often site of recurrent disease and are therefore often treated later with radiotherapy. In this phase II study, we evaluated toxicity and efficacy of the combination of continuous low dose (1 mIU/m2) s.c. IL-2 and thalidomide (200 mg once daily) in 22 patients with progressive metastatic renal cell cancer. In addition, 13 soft tissue lesions and two bone metastases in 13 patients were concurrently treated with fractionated radiotherapy. T cell number and activation in blood was measured by immunoflowcytometry. Nearly all patients developed grade 1-2 toxicity consisting of fatigue, sensory neuropathy, constipation and dizziness. Five patients had a grade 3-4 toxic event: four patients with deep venous thrombosis requiring anticoagulant therapy, and one patient who developed radiation myelopathy. On systemic response evaluation ten patients showed ongoing SD with a mean progression free survival of 9 months. One patient showed a PR (at an irradiated site). Regarding local response to irradiation, seven lesions showed a PR for a mean time period of 8.7 months, whereas seven were stable for 6 months. The radiation response of one lesion was not evaluable. Immunoflowcytometry showed an increase in number and activation of lymphocytes (mainly Natural Killer--NK-cells), which was absent or even decreased in irradiated patients. The combination of sc. low dose IL-2, thalidomide and radiotherapy is feasible, but relatively toxic and does not lead to higher responses at non-irradiated sites. The combination of immunotherapy and concurrent radiotherapy is effective at 60% of the relatively large evaluable sites. Progressive myelopathy developed in one patient, possibly due to radiotherapy in combination with thalidomide.
authors.affiliation: Division of Medical Oncology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Plesmanlaan 121, 1066, Amsterdam, The Netherlands.
authors.forename: J M
authors.initials: JM
authors.lastname: Kerst
authors.forename: A
authors.initials: A
authors.lastname: Bex
authors.forename: H
authors.initials: H
authors.lastname: Mallo
authors.forename: L
authors.initials: L
authors.lastname: Dewit
authors.forename: J B A G
authors.initials: JB
authors.lastname: Haanen
authors.forename: W
authors.initials: W
authors.lastname: Boogerd
authors.forename: H J
authors.initials: HJ
authors.lastname: Teertstra
authors.forename: G C
authors.initials: GC
authors.lastname: de Gast
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012983:Soft Tissue Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D015996:Survival Rate; D013601:T-Lymphocytes; D013792:Thalidomide / Q000008:administration & dosage
chemical_list: D007376:Interleukin-2; D013792:Thalidomide